Eidos Therapeutics Inc.

3 trials 1 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

13 Countries active

1 Unique IMPs

100% Results reported

Phase III

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

ACORAMIDIS HYDROCHLORIDE 3

All trials

3 total

Extension Study of ACT-EARLY Pending

2024-513676-18-00 Phase III 11 countries ACORAMIDIS HYDROCHLORIDE
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting

2024-513547-82-00 Phase III 12 countries ACORAMIDIS HYDROCHLORIDE
An Open-Label Extension and Safety Monitoring Study of Acoramidis(AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopath… Ended

2024-515092-36-00 Phase III 9 countries ACORAMIDIS HYDROCHLORIDE

Showing 1–3 of 3 trials

← All sponsors A–Z